3845 The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson’s disease: the Mobilise-D study
3845 Die Zukunft klinischer Studien? Mobilitätsmessung als Outcome-Maß bei Morbus Parkinson: die Mobilise-D-Studie
Age and Ageing · 05.02.2026 · 55 (Supplement_1)
DOI: 10.1093/ageing/afaf368.161 ↗Auf einen Blick
Bei 601 Menschen mit Morbus Parkinson und 232 Kontrollen wurden digitale Mobilitäts-Outcomes über 7 Tage erfasst. 20 von 24 Outcomes unterschieden sich signifikant zwischen den Gruppen.
Fragestellung
Beschreibung digitaler Mobilitäts-Outcomes bei Morbus Parkinson und Vergleich mit Kontrollen sowie nach Krankheitsstadium; außerdem Machbarkeit und Compliance.
Methode
Im Rahmen der Mobilise-D Clinical Validation and Extension Studies; 601 Menschen mit Morbus Parkinson und 232 gematchte Kontrollen trugen 7 Tage ein Wearable.
Ergebnisse
DMO-Daten lagen für 531 Personen mit Morbus Parkinson und 223 Kontrollen vor. In 20 von 24 DMOs bestanden signifikante Unterschiede; die Compliance war hoch.
Schlussfolgerung der Autor:innen
Unterschiedliche DMO-Muster nach Krankheitsstadium und zwischen Morbus Parkinson und Kontrollen sprechen laut Autor:innen für ihren Nutzen als sensitive, skalierbare Endpunkte.
Kernaussagen
- DMOs wurden mit einem Wearable 7 Tage im Alltag erfasst.
- 20 von 24 DMOs unterschieden sich signifikant zwischen den Gruppen.
- Hohe Compliance und Unterschiede nach Krankheitsstadium wurden berichtet.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 05.02.2026. Verfasst von A J Yarnall und 18 weiteren Autor:innen.
Themen: Mobilisation
Abstract (Originalsprache)
Introduction
A key challenge in clinical trials targeting disease modification in Parkinson’s disease (PD) is the lack of sensitive, precise, and patient-relevant outcome measures. Digital mobility outcomes (DMOs), captured using body-worn devices, offer a novel, objective means to assess real-world gait and mobility—domains often impaired early in PD. The Mobilise-D consortium was established to develop and validate DMOs in PD and other chronic conditions. The objective of this work was to describe DMOs in a large, representative international cohort of individuals with PD and compare to controls and across disease stage; and to determine compliance and feasibility.
Methods
As part of the Mobilise-D Clinical Validation and Extension Studies, real world mobility of individuals with PD (n = 601) and matched controls (n = 232) was assessed using a single wearable device for seven days. Data were processed to yield 24 technically validated DMOs, representing different domains of real-world walking and mobility performance.
Results
DMO data were available for 531 PD and 223 controls. Significant differences between the groups were observed in 20 of 24 DMOs. Compared to controls, PD participants exhibited shorter daily walking duration and lower step counts, walking at a higher cadence and in fewer walking bouts per day. Findings also varied by disease severity, with differences observed particularly between controls vs. mild (Hoehn and Yahr stage I-II) and mild vs. moderate (Hoehn and Yahr stage III) disease. Compliance rates were high.
Conclusion
Distinct DMO patterns across PD severity and between PD and controls support their utility as sensitive, scalable outcome measures for future clinical trials and therapeutic development.
Zitieren
APA
Yarnall, A. J., Alcock, L., Schlenstedt, C., Becker, C., Buekers, J., Caulfield, B., Cereatti, A., Din, S. D., Garcia-Aymeriche, J., Hansen, C., Long, M., Singleton, D., Ginis, P., Gassner, H., Nieuwboer, A., Hausdorff, J. M., Mirelman, A., Rochester, L., & Maetzler, W. (2026). 3845 The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson’s disease: the Mobilise-D study. Age and Ageing, 55(Supplement_1). https://doi.org/10.1093/ageing/afaf368.161
Vancouver
Yarnall AJ, Alcock L, Schlenstedt C, Becker C, Buekers J, Caulfield B, et al. 3845 The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson’s disease: the Mobilise-D study. Age and Ageing. 2026;55(Supplement_1). doi:10.1093/ageing/afaf368.161
BibTeX
@article{Yarnall2026,
author = {Yarnall, A J and Alcock, L and Schlenstedt, C and Becker, C and Buekers, J and Caulfield, B and Cereatti, A and Din, S D and Garcia-Aymeriche, J and Hansen, C and Long, M and Singleton, D and Ginis, P and Gassner, H and Nieuwboer, A and Hausdorff, J M and Mirelman, A and Rochester, L and Maetzler, W},
title = {3845 The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson’s disease: the Mobilise-D study},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {Supplement_1},
doi = {10.1093/ageing/afaf368.161}
}
EUVIMED